alexa An IgG Subtype Specific Flow Cross-match Assay Can Increase The Number Of Successful Transplants In Sensitized Renal Recipients
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

11th International Conference on Nephrology & Urology
March 22-23, 2017 Rome, Italy

Prakash Rao, Dayanand Deo, Shamkant Mulgaonkar and Praveen Kandula
NJ Sharing Network, USA
Barnabas Health Renal and Pancreas Transplant Division, USA
Posters & Accepted Abstracts: J Nephrol Ther
DOI: 10.4172/2161-0959.C1.037
A positive flow cytometric crossmatch (FXCM) is generally considered as a contraindication to a successful renal transplant. The standard FXCM does not distinguish between the various subtypes of the immunoglobulin molecule (IgG1, IgG2, IgG3, and IgG4). Of these, only IgG1 and IgG3 subtypes are capable of maximal complement activation with grave consequences. IgG2 and IgG4 are relatively benign. Using a new IgG subtype analysis FXCM, we can specifically detect and quantify the four IgG subtypes responsible for a positive crossmatch. Pre-transplant sera from seven recipients and blood samples from their respective donors were analyzed. PBMCs isolated from the donor blood samples were incubated with the patient and control sera for 30 minutes at 4°C. The cells were then incubated in the lyophilized custom cocktail of antibodies that specifically recognize the various IgG subtypes bound to the cells, followed by FCXM analysis. C1q testing on all sera was carried out. All cases showed the presence of non-complement activating antibodies as responsible for the positive FCXM (except patient CF). CF showed the presence of IgG3 antibodies with a negative C1q; probably the result of denatured antibodies. There were no episodes of clinical rejection or requirement for dialysis in the first week for any of the recipients. All recipients are alive and doing well more than 12 months following transplant. This assay has shown itself to be highly accurate in detecting the IgG subtype/s causing a positive FCXM, thus potentially resulting in successful transplants even in the presence of a positive FCXM.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version